Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 222.

https://doi.org/10.1182/blood-2025-222

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Blood (2025) 146 (Supplement 1): 89.

https://doi.org/10.1182/blood-2025-89

Published: 2025

Journal Articles

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Mahesh Swaminathan, Alexandre Bazinet, Koji Sasaki, Dan Fox, James Hill, Alex Bataller, Kelly Chien, Guillermo Montalban-Bravo, Danielle Hammond, Michelle Hildebrandt, Ian Bouligny, Wei-Ying Jen, Tapan Kadia, Koichi Takahashi, Courtney DiNardo, Elias Jabbour, Naval Daver, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2025-4634

Published: 2025

Journal Articles

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Blood (2025) 146 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2025-4613

Published: 2025

Journal Articles

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Blood (2025) 146 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2025-4294

Published: 2025

Journal Articles

Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center

Blood (2025) 146 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2025-6407

Published: 2025

Journal Articles

Dynamic biomarker trajectories predict outcomes in AML-associated hemophagocytic lymphohistiocytosis

Blood (2025) 146 (Supplement 1): 604.

https://doi.org/10.1182/blood-2025-604

Published: 2025

Journal Articles

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Hannah Goulart, Hagop Kantarjian, Koji Sasaki, Nitin Jain, Caitlin Rausch, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Danielle Hammond, Mahesh Swaminathan, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2025-1566

Published: 2025

Journal Articles

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2025-1556

Published: 2025

Journal Articles

Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: A prospective cohort study and quality improvement initiative (2019–2025)

Vanthana Bharathi, Kristofer Jennings, Jackie Broadway-Duren, Mahesh Swaminathan, Nitin Jain, William Wierda, Jan Burger, Dervy Salcedo, Stephanie Zelaya, Margaret Pace, Mariela Sivina, Alessandra Ferrajoli

Blood (2025) 146 (Supplement 1): 517.

https://doi.org/10.1182/blood-2025-517

Published: 2025

Journal Articles

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

Michelle Nwachukwu, Farhad Ravandi, Sanam Loghavi, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Nicholas Short, Elias Jabbour, Guillermo Montalban-Bravo, Alexandre Bazinet, Alex Bataller, Kelly Chien, Danielle Hammond, Mahesh Swaminathan, Wei-Ying Jen, Ian Bouligny, Naval Daver, Guillermo Garcia-Manero, Koji Sasaki

Blood (2025) 146 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2025-1620

Published: 2025

Journal Articles

A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia

Sankalp Arora, Hagop Kantarjian, Manuel Maroun, Gautam Borthakur, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Ghayas Issa, Kelly Chien, Abhishek Maiti, Maro Ohanian, Mahesh Swaminathan, Wei-Ying Jen, Farhad Ravandi, Hussein Abbas, Nicholas Short

Blood (2025) 146 (Supplement 1): 5226.

https://doi.org/10.1182/blood-2025-5226

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia

Alexandra Lovell, Emily Lee, Mikaela McCabe, Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Jan Burger, William Wierda

Blood (2025) 146 (Supplement 1): 5685.

https://doi.org/10.1182/blood-2025-5685

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center

Dynamic biomarker trajectories predict outcomes in AML-associated hemophagocytic lymphohistiocytosis

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: A prospective cohort study and quality improvement initiative (2019–2025)

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only